Protease-Activated Antifungal Conjugate for Selective Candida Biofilms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antifungal therapies face challenges in targeting Candida spp. with high specificity and low toxicity to the host, particularly in dealing with biofilm-related infections and drug-resistant strains, and there is a lack of effective antibody-based conjugates for fungal infections.
Innovation Solution
Development of an antibody fragment-based antifungal conjugate comprising an antimicrobial peptide, a camelid heavy chain antibody variable region fragment (VHH), a protease cleavage sequence, and a flexible polypeptide linker, designed to target Candida spp. biofilms and activate only upon interaction with pathogenic proteases, reducing host toxicity and enabling easy adaptation to drug-resistant forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antifungal therapies are used, then broad-spectrum coverage is achieved, but host toxicity increases and specificity against Candida spp. decreases
Solution Approach 1:
The invention divides the therapeutic agent into two separate components: an antibody fragment that provides targeting specificity and an antimicrobial peptide that provides killing activity. The antibody fragment specifically binds to Candida spp. cell wall components, while the antimicrobial peptide remains inactive until released at the target site, thereby reducing host toxicity while maintaining specificity.
Solution Approach 2:
A cleavable linker acts as an intermediary between the antibody fragment and antimicrobial peptide. This linker is designed to be stable in circulation but cleavable by fungal cell wall-associated proteases or phospholipases at the infection site, enabling controlled release of the antimicrobial peptide only where needed, thus reducing systemic host toxicity.
2Reliability
If antimicrobial peptides are used directly, then antimicrobial activity is achieved, but non-specific toxicity to host cells increases
Solution Approach 1:
The antibody fragment performs preliminary targeting by specifically binding to Candida spp. cell wall components before the antimicrobial peptide is activated. This preliminary recognition ensures that the antimicrobial peptide is only released at the correct target site, preventing non-specific toxicity to host cells while maintaining potent antimicrobial activity against Candida.
Solution Approach 2:
The cleavable linker serves as a protective intermediary that keeps the antimicrobial peptide inactive during circulation. The linker is specifically designed to be cleaved by fungal enzymes at the infection site, thereby activating the antimicrobial peptide only when and where it is needed, which eliminates non-specific host cell toxicity while preserving selectivity for Candida spp.
3Stability of the object's composition
If whole antibodies are used as carriers, then stability and half-life are improved, but molecular size and diffusion capability increase
Solution Approach 1:
The invention extracts only the essential antigen-binding fragment of the antibody (such as scFv or Fab fragments) rather than using the whole antibody. This extracted fragment retains the ability to specifically bind to Candida cell wall components while being significantly smaller in size, thereby improving diffusion capability and tissue penetration while maintaining adequate stability for the conjugate application.
Solution Approach 2:
The use of antibody fragments instead of whole antibodies creates a smaller, more transient conjugate that can be rapidly cleared from the system after performing its function. This approach accepts reduced circulation half-life in exchange for improved diffusion and reduced molecular size, which are critical for effective targeting of deep tissue infections.
4Ease of manufacture
If fixed-structure conjugates are used, then manufacturing simplicity is maintained, but adaptability to drug-resistant strains decreases
Solution Approach 1:
The invention creates a modular and dynamic conjugate structure where the antimicrobial peptide component can be easily exchanged or modified. The cleavable linker design and standardized antibody fragment platform allow rapid reconfiguration of the conjugate to target emerging drug-resistant Candida strains by simply changing the peptide component while maintaining the same targeting mechanism, thus achieving high adaptability without complicating manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate effectively targets Candida spp. biofilms with high specificity and reduced host toxicity, offering a prodrug mechanism that activates only at the infection site, enhancing therapeutic efficacy and allowing for easy modification to combat emerging drug-resistant strains.
Implementation Method 1
a signal protease cleavage sequence susceptible to cleavage by proteases belonging to the group consisting of membrane proteases, cell wall associated proteases, and secreted proteases of Candida spp., and proteases of host neutrophils
Data Source
AI summary
The present invention provides a novel antibody fragment based antifungal conjugate selectively targeting Candida spp. comprising of at least one antimicrobial peptide at one end of the conjugate, more particularly, human Histatin-5; an antibody fragment at the other end of the conjugate, specific against Candida spp. enolase, a virulence factor protease and biofilm specific antigen of Candida spp.; at least one signal protease cleavage sequence susceptible to cleavage by virulent protease secreted by Candida spp., secreted aspartyl proteinase-1 (SAP1); and at least one flexible polypeptide linker. The signal protease cleavage sequence and the flexible polypeptide linker are in tandem with each other and placed in between the antimicrobial peptide and the antibody. The in vitro MIC-99 of the conjugate against Candida spp., is in the range of 0.2-0.3 μM, more specifically, 0.25 μM or 250 nM.